Table 1.

Newcastle-Ottawa quality assessment scale cohort studies.

Study	Model	Selection				Comparability		Outcome
ROCK Inhibitor		1	2	3	4	1a	1b	1	2	3
Yun AD ROCKI 2013 [101]	AD	*	*	*	*	*		*	*	*
YU AD ROCKI 2020 [102]	AD	*	*	*	*	*	*	*	*	*
Yu AD ROCKI 2017 [103]	AD	*	*	*	*	*	*	*	*	*
Qing-fang AD ROCKI 2018 [104]	AD	*	*	*	*	*	*	*	*	*
Min-fang AD ROCKI 2020 [105]	AD	*	*	*	*	*	*	*		*
Manish AD ROCKI 2018 [106]	AD	*	*	*	*	*	*	*	*	*
K.H. Reeta AD ROCKI 2017 [107]	AD	*	*	*	*	*	*	*	*	*
Jogender AD ROCKI 2013 [108]	AD	*	*	*	*	*		*	*	*
Jiezhong Yu AD ROCKI 2018 [109]	AD	*	*	*	*	*	*	*	*	*
Ming ROCKI 2018 [110]	VD	*	*	*	*	*	*	*		*
Lin Huan ROCKI 2008 [111]	VD			*	*	*	*	*	*	*
PDE-5 inhibitor
Cuadrado Cognitive PDE5I 2011 [112]	AD		*	*	*	*	*	*	*	*
Cuadrado-Tejedor Cognitive PDE5I 2017 [113]	AD		*	*	*	*	*	*	*	*
Garcia Cognitive PDE5I 2013 [114]	AD		*	*	*	*	*	*	*	*
Gulisano Cognitive PDE5I 2018 [115]	AD		*	*	*	*	*	*		*
Puzzo Cognitive PDE5I 2009 [116]	AD		*	*	*	*	*	*		*
Mohamed Cognitive PDE5I 2021 [117]	AD		*	*	*	*	*	*	*	*
Venkat Cognitive PDE5I 2019 [118]	AD		*	*	*	*	*	*	*	*
Zhang Cognitive PDE5I 2018 [119]	AD		*	*	*	*	*	*		*
Zhu Cognitive PDE5I 2015 [120]	AD		*	*	*	*		*	*	*
Bhatia Cognitive PDE5I 2019 [121]	VD		*	*	*	*	*	*		*
Gulati Cognitive PDE5I 2014 [122]	VD		*	*	*	*	*	*		*
Gulati P Cognitive PDE5I 2014 [123]	VD		*	*	*	*	*	*		*

* Indication means that the publication corresponds to the part of the Newcastle-Ottawa quality assessment. AD: Alzheimer’s disease, VD: vascular dementia, PDE5I: phosphodiesterase 5 inhibitor, ROCKI: rho-associated kinase inhibitor.